Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Cancer Cell · 2024-03 · 42 (3) · 413-428.e7
DOI: 10.1016/j.ccell.2024.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-03. Verfasst von Xinyuan Tong und 39 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese A…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Squamous Cell, Acetonitriles, Piperazines. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
- Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical…
- MOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.
- State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Acad…
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Biological and biomedical sciences program, Harvard Medical School, Bost…
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Natural Science Foundation of China
- Bristol-Myers Squibb
- Hale Family Center for Pancreatic Cancer Research
- National Key Research and Development Program of China
- Eli Lilly and Company
- Lustgarten Foundation
Zitieren
APA
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., Xue, Y., Hover, L., Mukhopadhyay, S., Sherman, F., Myndzar, K., Sahu, P., Gao, Y., Li, F., Li, F., …, & Ji, H. (2024). Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell, 42(3), 413-428.e7. https://doi.org/10.1016/j.ccell.2024.01.012
Vancouver
Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42(3):413-428.e7. doi:10.1016/j.ccell.2024.01.012
BibTeX
@article{Tong2024,
author = {Tong, Xinyuan and Patel, Ayushi S and Kim, Eejung and Li, Hongjun and Chen, Yueqing and Li, Shuai and Liu, Shengwu and Dilly, Julien and Kapner, Kevin S and Zhang, Ningxia and Xue, Yun and Hover, Laura and Mukhopadhyay, Suman and Sherman, Fiona and Myndzar, Khrystyna and Sahu, Priyanka and Gao, Yijun and Li, Fei and Li, Fuming and Fang, Zhaoyuan and Jin, Yujuan and Gao, Juntao and Shi, Minglei and Sinha, Satrajit and Chen, Luonan and Chen, Yang and Kheoh, Thian and Yang, Wenjing and Yanai, Itai and Moreira, Andre L and Velcheti, Vamsidhar and Neel, Benjamin G and Hu, Liang and Christensen, James G and Olson, Peter and Gao, Dong and Zhang, Michael Q and Aguirre, Andrew J and Wong, Kwok-Kin and Ji, Hongbin},
title = {Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {3},
pages = {413--428.e7},
doi = {10.1016/j.ccell.2024.01.012}
}
EUVIMED